Replies to post #72272 on Regen BioPharma Inc (RGBP)

[hunterj20]

Just WOW

[Skiluc]

The wake up will be real.

[Goldstrike]

An intelligent post and a good case for the defense of the POS RGBP.

EXCEPT companies like Gilead or Amgen are showing zero interest in Koot's outfit. Koots can't even keep a board of advisors together for gawds sake.

[Skiluc]

600M in debt and it was bought for 12B. We have a tiny fraction of that in debt! Does that mean we have that big of a runway to raise for advancement? Bingo!

And not to mention our IP is multiples better. $20B? $50B? Boom boom a vroom.

Dont let anyone fool you into our IP being untested. What did Chemdiv do? Hello? And thats just one of many arguments. What was the nature of Eli Lilly and Regen collaboration? Was it not active research? Testing of molecules, to be specific? Yes. Yes it was.

Dont be fooled!! Know what you Own!

Amazing contribution Carter. Much Appreciated!

[OTCShotCaller]

EXCELLENT POST CARTER!! A SUPERB REVIEW OF THE BIOTECH SECTOR!!!

Very clearly you've done your homework.

I hope everyone here is paying attention to your post for reason it spells out what can and does happen in the Biotech sector especially related to largely "unknown" Biopharmas with no earnings and heavily in debt, BUT with a drug patent pipeline worth Billions.

RGBP has at least 20 with (1) FDA Approved Patent for (2) INDs for entering clinical trials to treat pancreatic and colon cancer...and to boot they have partnership licensing arrangements with Oncology Pharma to take that patent into clinical trials authorized by the FDA. That's an epic "game changer" for RGBP! This totally changed its perceived Market Value overnight to ALL the Big Pharmas out there.

That Patent has at least a 95% chance of passing through all 4 Clinical Trial phases and making it to Market. It is a Multi-Billion Dollar Patent with mRNA disruptive biotechnology which like Kite Pharma, makes them a prime target for Buy Out by a Big Pharma. The chances of that happening are very high...more likely than not!

Lastly, I find it very interesting and coincidental that Kite Pharma, just before they were bought out by Gilead for $12 Billion, were a developmental stage Biopharma engaged in discovery of immune based therapies to treat various cancers 100% identical to RGBP! And not only this, like RGBP, they were based in Los Angeles, California.

History repeats itself....

Be well and prosper

[Carter]

Biotech Valuations con't... and the import of the high # of "shots on goal" with RGBP's 20+ mRNA Patents/NR2F6.

The more shots on goal "the greater the likelihood that their approach will yield a blockbuster product."

From the McKinsey & Company 2020 whitepaper: Delivering innovation: 2020 oncology market outlook

In addition to abundant organic R&D at both large pharmaceutical companies and numerous clinical-stage biotechs, we have observed a spate of multibillion dollar oncology-focused acquisitions (such as Pfizer’s 2019 acquisition of Array BioPharma for $11 billion) and partnerships (including a $3 billion collaboration between AbbVie and Genmab on bispecific antibodies). Excitement about oncology targets has driven high deal premiums. Over the past five years, the median oncology acquisition premium was approximately 100 percent for transactions with a deal value of more than $5 billion.

In the commercial setting, most major pharmaceutical companies are focused on synergistic subsets of indications with overlapping call points and opinion-leader relationships. In the R&D setting, however, beyond their hypotheses, scientists don’t know where a new therapy will work. So we see most players exploring a wider set of indications by taking more “shots on goal”—the more indications they address, the greater the likelihood that their approach will yield a blockbuster product

The past five years have been characterized by a growing excitement about novel modalities including cell therapy, viral vectors, RNA therapy, and stem-cell therapies.
https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/delivering-innovation-2020-oncology-market-outlook#